drugset / Trial / NCT04039347
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
Timeline
- Start
- 2020-03-12
- Primary completion
- 2026-02-25
- Completion
- 2026-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 5 mg | Inhaled |
| Subject | Cyclosporine | Peptide | 10 mg | Inhaled |